Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: HRV Pharma is using the Shodhana alliance to turn its AI‑enabled “Virtual API” model into tangible, regulated assets, starting with a pharmaceutical...
